Special Issue

Novel Targeted Cancer Therapeutics and Personalized Medicine

Message from the Guest Editors

Although there has been continuous improvement in the survival and other outcomes of patients with cancer over time, cancer patients still have high mortality rates. Moreover, thus far scientists have striven to develop a novel therapy based on the characteristics of numerous cancers. For instance, recent research revealed elevated immune system activity through immune checkpoint-related therapy as a novel targeted therapeutic to cure cancers. Furthermore, recent studies have indicated distinct features and heterogeneity of tumors through high throughput sequencing and mass spectrometry analysis. Therefore, it is critical to identify novel targets for cancer therapeutics and develop personalized medicine that can be used in the treatment of cancer patients. Moreover, aiming at the treatment of molecular and cellular variability under different individual cancer patients is a new direction for cancer research. In this Special Issue, the current findings, as well as future research directions on the role of novel targets, mechanisms, and specific genes of cancers will be discussed.

Guest Editors

Dr. Wei-Jan Wang

Research Center for Cancer Biology, Department of Biological Science and Technology, China Medical University, Taichung 40604, Taiwan

Dr. Chih-Yang Wang

Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science, Taipei Medical University, Taipei 11031, Taiwan

Deadline for manuscript submissions

closed (31 December 2022)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/103899

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

MDPI